Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and MYC-Driven Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAX drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAX Recombinant Protein (bHLH-LZ Domain / Full-Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View MAX Products |
| Gene Delivery | MAX Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and transcriptional reporter assays. |
View MAX Products |
| Benchmark Ab | Anti-MAX Recombinant Antibody High-affinity positive control for Western Blot, ChIP, and ELISA assays. |
View MAX Products |
| Validator | MAX siRNA Set Target-specific knockdown verification in cancer cell lines. |
View MAX Products |
| Related Target A | MYC Primary heterodimerization partner. Crucial for establishing MYC-MAX interaction disruption assays. |
View MYC Products |
| Related Target B | MXD1 Antagonistic partner competing with MYC for MAX binding. Essential for selectivity screening. |
View MXD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening accuracy | High-purity human recombinant MAX and MYC partner proteins with verified theoretical MW and native-like dimerization capacity. |
| Dimerization specificity verification | Homolog and competitor panels (MXD1, MGA) strictly verified by mass spectrometry to eliminate false-positive PPI disruptors. |
| Lack of clinical-grade positive controls | Sequence-verified benchmark antibodies and reference tool compounds annotated for assay validation. |
| Off-target effects in phenotypic assays | Validated siRNA sets included for target-specific knockdown to verify compound mechanism of action. |
Live MAX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAX therapeutics is intensifying, with major players shifting focus from traditional transcription factor inhibition to targeted protein-protein interaction (PPI) disruption and PROTAC-mediated degradation. As first-generation direct MYC inhibitors face delivery and stability challenges, targeting the MAX node—either via disrupting the MYC-MAX heterodimer or utilizing MAX as an anchor for degradation—is emerging as the next wave of R&D targeting historically "undruggable" oncogenic transcription factors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Disruptor) | Kronos Bio, Cardiff Oncology | Small Cell Lung Cancer (SCLC), Triple-Negative Breast Cancer (TNBC) | High-throughput Screening (HTR/FP assays requiring highly stable, pure MAX/MYC recombinant proteins) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Hematological Malignancies, Prostate Cancer | Target Engagement Validation (Requires sequence-verified MAX and E3 ligase complexes) |
| Mini-protein / Peptide | Peptomyc (Omomyc) | Solid Tumors, Glioma | Cellular Uptake and Dimerization Assays (Requires Lentivirus for stable reporter cell line generation) |